[A18-22] Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V
Last updated 02.07.2018
Project no.:
A18-22
Commission:
Commission awarded on 29.03.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Children's and adolescents' health
Severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
Added benefit not proven as the appropriate comparator therapy (best supportive care) was not implemented in any of the studies
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2018-09-20 A G-BA decision was published.